Skenan LP is a medicinal product whose main active ingredient is morphine sulfate in a modified-release dosage form. It is a potent opioid analgesic used for the treatment of severe and very severe pain syndromes when other pain management methods are insufficient. Thanks to its prolonged action, it provides a stable level of analgesia for an extended period, which is particularly important for patients with chronic pain.
Overview of the Drug
Skenan LP is available as modified-release capsules, which allows for maintaining therapeutic concentrations of morphine in the blood for up to 24 hours with once or twice daily dosing. This significantly improves patients' quality of life by reducing the need for frequent pain medication. The drug is intended for various types of pain, including oncological pain, post-operative pain, and acute traumatic pain, when non-narcotic analgesics are ineffective.
Mechanism of Action
The active substance of Skenan LP, morphine, is an agonist of opioid receptors (mu-, kappa-, and delta-). Its analgesic effect is primarily mediated by stimulating mu-receptors in the central nervous system. Activation of these receptors leads to altered pain perception, reduced emotional response to painful stimuli, and an overall sedative effect. Morphine also depresses the respiratory center, causes miosis, reduces gastrointestinal motility, increases sphincter smooth muscle tone, and produces euphoric effects, which accounts for its potential for dependence development.
Typical Uses
- Management of severe chronic pain: Especially in oncology patients, where continuous and long-term analgesia is required.
- Post-operative pain relief: In cases of intense pain requiring potent analgesia.
- Pain from injuries: For severe injuries accompanied by significant pain.
- Neuropathic pain: In some cases where other treatments have been ineffective.
The dosage of Skenan LP is individually determined by a physician and depends on the intensity of pain, the patient's response to treatment, and previous opioid experience. Strict adherence to the prescribed dosing regimen is crucial.
Safety and Side Effects
Like all opioids, Skenan LP has a range of serious side effects. The most common include constipation, nausea, vomiting, drowsiness, dizziness, respiratory depression, euphoria, and dysphoria. Prolonged use can lead to physical and psychological dependence. Morphine overdose is extremely dangerous and can result in severe respiratory depression, coma, and death. Contraindications include acute respiratory failure, traumatic brain injuries, paralytic ileus, acute alcohol intoxication, and hypersensitivity to morphine.
Comparison with Other Analgesics
Skenan LP is a potent opioid analgesic, justified for high-intensity pain not controlled by other medications.
| Parameter | Skenan LP (Morphine) | Tramadol | Ibuprofen |
|---|---|---|---|
| Drug Class | Opioid analgesic (strong) | Opioid analgesic (weak/moderate) | NSAID |
| Mechanism of Action | Opioid receptor agonist (primarily mu) | Opioid receptor agonist, norepinephrine and serotonin reuptake inhibitor | COX-1 and COX-2 inhibitor |
| Pain Intensity | Severe to very severe | Moderate to severe | Mild to moderate |
| Dependence Potential | High | Low/moderate | None |
| Duration of Action | Prolonged (up to 12-24 hours for LP form) | Short-acting (4-6 hours) | Short-acting (4-8 hours) |
| Typical Side Effects | Constipation, nausea, vomiting, respiratory depression, drowsiness | Nausea, dizziness, drowsiness, constipation | Dyspepsia, GI ulcer, renal failure |
Expert Perspective
“The use of prolonged-release morphine formulations, such as Skenan LP, is a cornerstone in the therapy of chronic severe pain, especially of oncological origin. Stable maintenance of the analgesic effect without peaks and troughs significantly improves patients' quality of life and allows them to lead more active lives. However, it is critically important to strictly follow dosing protocols and carefully monitor the patient for side effects and the development of tolerance.”
— Clinical Pharmacologist, Palliative Care Specialist
Conclusion
Skenan LP is a powerful and effective agent for severe pain management, especially when a prolonged analgesic effect is needed. However, its use requires strict medical supervision due to the risk of serious side effects and dependence. Self-medication with this drug is strictly prohibited. Before starting, changing the dosage, or discontinuing Skenan LP, it is always necessary to consult a qualified physician who will assess all risks and benefits and determine the individual treatment regimen.